The efficacy and tolerability of modafinil for fatigue and daytime sleepiness in cancer patients: preliminary study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001412

Enrollment

Registered

2015-03-12

Start date

2014-11-13

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : modafinil 200mg per oral, daily for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?solid cancer patient ?age of 20-65 years old ?Subjects who scored =4 or >4 on the Brief Fatigue Inventory ?Subjecst with informed consent

Exclusion criteria

Exclusion criteria: ?metastatic cancer(stage IV) ?with psychotic symptoms such as delusion and hallucination or with suicidal risk ?with delirium or dementia ?current medication of cognitive enhancer or psychostimulant ?uncontrolled medical illness ?current medications that are contraindicated or not recommended for co-administration with modafinil

Design outcomes

Primary

Measure	Time frame
severity of fatigue (score for Brief Fatigue Inventory)	—

Secondary

Measure	Time frame
quantitative electrocephalography;cognitive function test;sleepwake cycle;depression/anxiety	—

Countries

Korea, Republic of

Contacts

Public ContactHyeyoun Park

Seoul National University Bundang Hospital

Outcome results